Cathie's Ark LogoCathie's Ark
BEGIN TYPING TO SEARCH BY TICKER
Beam Therapeutics Inc Logo

ARKK Holdings of Beam Therapeutics (BEAM) - Updated Daily

Date
Direction
Shares
Fund Weight
Fund
July 28, 2022
SELL55.804k0.0384%ARKK
July 13, 2022
SELL163.896k0.0953%ARKK
April 14, 2022
BUY38.691k0.0171%ARKK
April 13, 2022
BUY7.426k0.0035%ARKK
April 11, 2022
BUY12.538k0.0055%ARKK

Key Statistics

DateAugust 08, 2022Revenue
Expected$8.39m
Actual▫️
EPS
Expected
Actual▫️
🕵🏼Found In🏷Last Price
ARKKARKG$60.96
⚖️Weighting🧢Market Cap
4.21%$4.28b
🏋🏿‍♂️Weight Rank In ARKK🧮Price to Sales
1071.07
🏋️‍♀️Weight Rank Across All Funds🌏Country
10🇺🇸United States
💳ARK Estimated Cost Average🎫ARK Ownership Percent
$84.559.55%
Description
Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam's suite of gene editing technologies is anchored by base editing, a proprietary technology that enables precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Website
beamtx.com

Research Notes and Commentary for BEAM